Option Care Health (OPCH) to Release Earnings on Wednesday

Option Care Health (NASDAQ:OPCH) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, October 30th. Analysts expect Option Care Health to post earnings of $0.31 per share for the quarter. Option Care Health has set its FY 2024 guidance at EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

Option Care Health (NASDAQ:OPCH) last posted its earnings results on Wednesday, July 31st. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.03. The company had revenue of $1.23 billion during the quarter, compared to analyst estimates of $1.17 billion. Option Care Health had a return on equity of 14.82% and a net margin of 4.60%. Option Care Health’s revenue was up 14.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.63 earnings per share. On average, analysts expect Option Care Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Option Care Health Stock Down 0.6 %

Option Care Health stock opened at $30.34 on Wednesday. The business has a fifty day moving average of $31.08 and a two-hundred day moving average of $30.11. The company has a quick ratio of 1.36, a current ratio of 1.76 and a debt-to-equity ratio of 0.78. The firm has a market cap of $5.27 billion, a P/E ratio of 19.96, a P/E/G ratio of 2.21 and a beta of 1.29. Option Care Health has a twelve month low of $26.11 and a twelve month high of $34.63.

Insider Transactions at Option Care Health

In other news, Director Elizabeth Quadros Betten sold 47,531 shares of the company’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $31.09, for a total transaction of $1,477,738.79. Following the transaction, the director now directly owns 21,339 shares of the company’s stock, valued at approximately $663,429.51. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Director Elizabeth Quadros Betten sold 47,531 shares of the company’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $31.09, for a total transaction of $1,477,738.79. Following the transaction, the director now directly owns 21,339 shares of the company’s stock, valued at approximately $663,429.51. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Michael H. Shapiro sold 23,217 shares of the company’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.95, for a total value of $718,566.15. Following the completion of the transaction, the chief financial officer now directly owns 247,317 shares in the company, valued at approximately $7,654,461.15. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Barrington Research upped their target price on Option Care Health from $38.00 to $40.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. JMP Securities upped their target price on Option Care Health from $36.00 to $37.00 and gave the stock a “market outperform” rating in a report on Monday, September 30th.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.